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ABSTRACT
This could be the beginning of a new molecular era for the diagnosis of infectious diseases. Biological
chips (biochips or microarrays and labchips) offer a potentially important shortcut to early diagnosis
and treatment. It is also possible to develop multiplex assays for use in complex diagnostic situations;
however, this technology depends crucially on the robotics developed to support these functions, and
the soundness of the mathematics employed to analyse the output. Although the number of research
applications is increasing, the question as to when, or if, chip-mediated techniques will be used routinely
in the infectious disease clinic remains unanswered at present.
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Several types of biological chips (microarrays) [1]
are potentially useful for the study of microbial
infections, and various numerical procedures
(e.g., data mining and data-warehouse robotic
methods) exist for analysing the numerical
results obtained. Microarrays can be designed
by the user, and some commercial kits are also
now available (e.g., http://www.affymetrix.com;
http://www.sequenom.com).
Two types of biological chip can be used in
clinical microbiology: first, microarrays [2] or
biochips, which are biological microchips used
for diagnostics or research concerning new drugs
or their targets (pharmacogenomics) [3]; and
second, labchips, which are useful as a multiple-
test diagnostic tool (http://www.agilent.com),
especially for ‘point-of-care testing’. This latter
term refers to diagnostic tests performed outside
the laboratory in the immediate proximity of
patients (whether hospitalised or not), and such
tests may be particularly useful in emergency
situations, disasters and when investigating out-
breaks.
Biochips can be elaborated by different proce-
dures, but the most common are photolithography
(as for informatics chips) and spectrophotometric
detection. Biochips can be used to develop multi-
plexed assays [4] for use in complex situations,
and are thus elegant tools for difficult situations
where a non-conventional mathematical approach
is in order (i.e., they provide easy solutions for
complex problems). Labchips are ‘nanolabora-
tories’, in that they use nanotechnology to perform
PCR, chromatography, electrophoresis and other
techniques, all on a single chip. A single labchip
can be used to perform several investigations on a
single sample simultaneously. Some labchips
allow multiplexed systems, so that several tech-
niques can be used simultaneously with several
samples on a single chip.
The use of biochips (microarrays) involves a
number of different steps that have been des-
cribed in detail elsewhere [1–4], but the sample to
be analysed is usually prepared by PCR and
labelled with a fluorescent (occasionally chemilu-
minescent or radioactive) molecule. Following
hybridisation with the chip, the results obtained
are normally revealed with the aid of a laser
beam, scanned, and compared with genetic
databases. Similarities in the databases are deter-
mined by data mining systems [5], and the results
are expressed as a percentage. In our own
laboratory, the data are transferred, following
validation, into the database of a genetic
laboratory information management system by a
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data-warehouse procedure. Such methods are
based on different types of cluster analysis
(Table 1) [6]. Results are conserved for future
analysis using software that updates the database
continuously. However, the clustering method
used may not always be the same, and the
selection of a clustering procedure should be
done by an expert in applied mathematics. Simi-
larly, the breakpoint in ‘cut-off’ studies must be
determined according to epidemiological defini-
tions derived from previous large conventional
studies. The robotics used to support these func-
tions usually depend on fuzzy logic [7], and the
tools required are variable, again requiring the
advice of experts in this field. The most common
approaches are genetic algorithms and neural
networks, but any method used in artificial
intelligence [8] can be applied.
Microarrays have already been used to investi-
gate genetic expression and polymorphisms in
certain microorganisms, such as Mycobacterium
tuberculosis, Escherichia coli, Staphylococcus aureus
and Helicobacter pylori, not only in the context of
historical epidemiological research, but also as a
rapid diagnostic method for use with critically ill
patients or in the case of possible outbreaks of
infection. Drug-induced alterations in gene
expression have been studied with Streptococcus
pneumoniae and industrial yeasts [9], and the
pathogenesis of infection is a frequent topic of
microarray-related research in the recent litera-
ture [10–12]. In M. tuberculosis, investigations of
the effect of isoniazid on gene expression [13] and
gene-mapping studies [14] have been performed
with microarrays. Biochips have been used to
determine antimicrobial resistance in Strep. pneu-
moniae [15], and to investigate the genetic diver-
gence and fitness of sub-clones of H. pylori [16].
Microarrays have also been used in the design of
vaccines [17], for serodiagnostics [18,19], research
into genetic targets for drugs [20], study and
control of parasites [21,22], diagnosis and treat-
ment of viral infections [23] and the development
of new antimicrobials. An algorithm used for
diagnostics [24] must be modified continuously
because DNA is a structure that evolves con-
stantly. It must also be emphasised that this
technology is crucially dependent upon the
soundness of the mathematics employed.
This is the beginning of a new molecular era for
the diagnosis and treatment of infectious diseases,
and biological chips (http://www.lab-on-a-chip.
com) constitute a very important potential short-
cut to early diagnosis and treatment. Biological
chips seem to have an expanding future, but not
without some obvious drawbacks (Table 2). How-
ever, there are two main reasons why the possible
introduction of these techniques into the clinical
microbiology laboratory should be investigated:
first, the desire of clinicians to increase the quality
of care for patients; and second, the potential
benefits for health care management in general, in
terms of economics and in the general context of
quality assurance and efficient resolution of
health care problems. The current challenge is to
establish the criteria for development of the
necessary equipment and intelligent software.
Cost may or may not be the most important
problem, depending on local circumstances, but it
will be necessary to standardise the technical
components of the system and establish appro-
priate technical support and quality management
arrangements. Perhaps the most important limit-
ing factor is the shortage of qualified personnel,
especially experts in the mathematical models
involved in these techniques. Although the
Table 1. Cluster analysis methods for health care studies
Hierarchical methods
Agglomerative methods
Space contracting
Space dilating
Space conserving
Single linkage
Complete linkage
Average linkage
Centroid
Median
Ward’s method
Divisive methods
Partitioning methods
Convergent ‘k-means’ algorithm
Density and mode analysis
Leader algorithm
Table 2. Advantages and disadvantages associated with
the adoption of microarrays and labchips in clinical
diagnostics
Advantages
Efficiency
Clarity
Safety
Possibility of multiplex and parallel assays
‘Point-of-care’ tests
Diagnostics in complex situations
Disadvantages
Cost of robotics and supplies is high
Personnel require special training and complementary knowledge
Participation of mathematical experts is required
Protocols are not yet well-defined
Definitive laws concerning the techniques and the personnel
using them do not exist
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number of research applications is increasing,
the question as to when, or if, chip-mediated
techniques will be used routinely in the infectious
disease clinic remains unanswered at present.
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